LOMAIRA- phentermine hydrochloride tablet
LOMAIRA by
Drug Labeling and Warnings
LOMAIRA by is a Prescription medication manufactured, distributed, or labeled by KVK-TECH, INC., AVANTHI INC.. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
-
DESCRIPTION
Phentermine hydrochloride is a sympathomimetic amine anorectic. Its chemical name is α,α,-dimethylphenethylamine hydrochloride. The structural formula is as follows:
Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.
LOMAIRA™ tablet is available as an oral tablet containing 8 mg of phentermine hydrochloride (equivalent to 6.4 mg of phentermine base). Each LOMAIRA™ tablet also contains the following inactive ingredients: Corn Starch, Magnesium Stearate, NF, Microcrystalline Cellulose 102, NF, Stearic Acid, NF, FD&C Blue #1, Sucrose and Pharmaceutical Glaze.
-
CLINICAL PHARMACOLOGY
Mechanism of Action
Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and dll-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.
Pharmacodynamics
Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Pharmacokinetics
Specific Populations
Renal Impairment
Phentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.
-
CLINICAL STUDIES
In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with “anorectic” drugs lost more weight on the average than those treated with placebo and diet.
The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an “anorectic” drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.
The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks’ duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.
-
INDICATIONS AND USAGE
LOMAIRA™ tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m 2, or greater than or equal to 27 kg/m 2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).
Below is a chart of body mass index (BMI) based on various heights and weights.
BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.
BODY MASS INDEX (BMI), kg/m 2
The limited usefulness of agents of this class, including phentermine (see Clinical Pharmacology), should be measured against possible risk factors inherent in their use such as those described below.
-
CONTRAINDICATIONS
History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)
During or within 14 days following the administration of monoamine oxidase inhibitors
Hyperthyroidism
Glaucoma
Agitated states
History of drug abuse
Pregnancy (see Precautions)
Nursing (see Precautions)
Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines -
WARNINGS
Coadministration with Other Drug Products for Weight Loss
LOMAIRA™ tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.
Primary Pulmonary Hypertension
Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.
Valvular Heart Disease
Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.
Development of Tolerance, Discontinuation in Case of Tolerance
When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.
Effect on the Ability to Engage in Potentially Hazardous Tasks
Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Risk of Abuse and Dependence
Phentermine is related chemically and pharmacologically to amphetamine (d- and dll-amphetamine) and other related stimulant drugs have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See Adverse Reactions/ Drug Abuse and Dependence and Overdosage.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Usage with Alcohol
Concomitant use of alcohol with phentermine may result in an adverse drug reaction.
-
PRECAUTIONS
Information for Patients
Patients must be informed that phentermine hydrochloride is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended (see Indications and Usage and Warnings).
Patients must be instructed on how much phentermine to take, and when and how to take it (see Dosage and Administration).
Advise pregnant women and nursing mothers not to use phentermine (see Precautions).
Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:
Development of primary pulmonary hypertension (see Warnings)
Development of serious valvular heart disease (see Warnings)
Effects on the ability to engage in potentially hazardous tasks (see Warnings)
The risk of an increase in blood pressure (see Warnings and Adverse Reactions)
The risk of interactions (see Contraindications, Warnings, and Precautions/ Drug Interactions)The patients must also be informed about
the potential for developing tolerance and actions if they suspect development of tolerance (see Warnings) and
the risk of dependence and the potential consequences of abuse (see Warnings, Drug Abuse and Dependence, and Overdosage).Tell patients to keep phentermine in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.
Drug Interactions
Monoamine Oxidase Inhibitors
Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.
Alcohol
Concomitant use of alcohol with phentermine may result in an adverse drug reaction.
Insulin and Oral Hypoglycemic Medications
Requirements may be altered (see Warnings)
Adrenergic Neuron Blocking Drugs
Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.
Pregnancy
Pregnancy Category X
Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and dll-amphetamine) (see Clinical Pharmacology ). Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
Nursing Mothers
It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.
Geriatric Use
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Renal Impairment
Phentermine was not studied in patients with renal impairment. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment (see Clinical Pharmacology).
-
ADVERSE REACTIONS
The following adverse reactions are described, or described in greater detail, in other sections:
- Primary pulmonary hypertension (see Warnings)
- Valvular heart disease (see Warnings)
- Effect on the ability to engage in potentially hazardous tasks (see Warnings)
- Withdrawal effects following prolonged high dosage administration (see Drug Abuse and
Dependence)The following adverse reactions to phentermine have been identified:
Cardiovascular
Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.
Central Nervous System
Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.
-
DRUG ABUSE AND DEPENDENCE
Abuse
Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.
Dependence
Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
-
OVERDOSAGE
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Acute Overdosage
Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.
Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine ®, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.
Chronic Intoxication
Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See Drug Abuse and Dependence.
-
DOSAGE AND ADMINISTRATION
Dosage should be individualized to obtain an adequate response with the lowest effective dose.
The usual adult dose is one tablet three times a day ½ hour before meals. This tablet is scored to facilitate administering one half of the usual dosage for patients not requiring the full dose. Phentermine hydrochloride is not recommended for use in pediatric patients less than or equal to 16 years of age.Late evening medication should be avoided because of the possibility of resulting insomnia.
-
HOW SUPPLIED/STORAGE AND HANDLING
LOMAIRA™ is available as follows:
LOMAIRA™ 8 mg is supplied as white butterfly shaped tablets with blue speckles, debossed “K1” on one side and bisected on the other side.
Bottles of 30, NDC: 10702-001-03
Bottles of 60, NDC: 10702-001-06
Bottles of 90, NDC: 10702-001-09
Bottles of 250, NDC: 10702-001-25
Bottles of 500, NDC: 10702-001-50
Bottles of 1000, NDC: 10702-001-10
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).
Keep out of the reach of children.
Manufactured by:
KVK-Tech, Inc.
110 Terry Drive
Newtown, PA 18940
Item ID# 006178/07
Manufacturer’s Code: 10702 09/16
-
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
30 Tablets
NDC 10702- 001-03
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
30 Tablets Rx Only
KVK-TECH, INC.
60 Tablets
NDC 10702- 001-06
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
60 Tablets Rx only
KVK-TECH, INC.
90 Tablets
NDC 10702- 001-09
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
90 Tablets Rx only
KVK-TECH, INC.
250 Tablets
NDC 10702- 001-25
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
250 Tablets Rx only
KVK-TECH, INC.
500 Tablets
NDC 10702- 001-50
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
500 Tablets Rx only
KVK-TECH, INC.
1000 Tablets
NDC: 10702-001-10
LOMAIRA TM CIV
(phentermine hydrochloride USP) tablets
8 mg
Rx only 1000 Tablets
KVK-TECH, INC.
-
INGREDIENTS AND APPEARANCE
LOMAIRA
phentermine hydrochloride tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 10702-001 Route of Administration ORAL DEA Schedule CIV Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength PHENTERMINE HYDROCHLORIDE (UNII: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP) PHENTERMINE HYDROCHLORIDE 8 mg Inactive Ingredients Ingredient Name Strength STARCH, CORN (UNII: O8232NY3SJ) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) STEARIC ACID (UNII: 4ELV7Z65AP) FD&C BLUE NO. 1 (UNII: H3R47K3TBD) SUCROSE (UNII: C151H8M554) Product Characteristics Color white, blue (Speckles) Score 2 pieces Shape FREEFORM (Butterfly Shape) Size 3mm Flavor Imprint Code K;1 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 10702-001-03 30 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 2 NDC: 10702-001-06 60 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 3 NDC: 10702-001-09 90 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 4 NDC: 10702-001-25 250 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 5 NDC: 10702-001-50 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 6 NDC: 10702-001-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/12/2016 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA203495 09/12/2016 Labeler - KVK-TECH, INC. (173360061) Registrant - AVANTHI INC. (832316694) Establishment Name Address ID/FEI Business Operations KVK-TECH, INC. 173360061 manufacture(10702-001)
Trademark Results [LOMAIRA]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 LOMAIRA 86579836 5191785 Live/Registered |
AVANTHI, Inc. 2015-03-28 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.